

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.**

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Chen, Zhijian J.
 Application No.: N/A Group No.: Not Yet Assigned
 Filed: March 26, 2004 Examiner: Not Yet Assigned
 For: KINASE CAPABLE OF SITE-SPECIFIC PHOSPHORYLATION OF IKB-A

Mail Stop Patent Application
 Commissioner for Patents
 P.O. Box 1450
 Alexandria, VA 22313-1450

TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT**IDENTIFICATION OF TIME OF FILING THE ACCOMPANYING
INFORMATION DISCLOSURE STATEMENT**

1. The information disclosure statement submitted herewith is being filed:

Within three months of the filing date of the application or date of entry into the national stage of an international application or before the mailing date of a first Office action on the merits, whichever event occurs last. 37 C.F.R. section 1.97(b).

OR

After three months of the filing date of this national application or the date of entry of the national stage as set forth in Section 1.491 in an international application or after the mailing date of the first Office action on the merits, whichever event occurred last but *before* the mailing date of either:

- (1) a final action under Section 1.113,
- (2) a notice of allowance under Section 1.311, or

CERTIFICATION UNDER 37 C.F.R. SECTIONS 1.8(a) and 1.10*

I hereby certify that, on the date shown below, this correspondence is being:

MAILING

deposited with the United States Postal Service in an envelope addressed to Mail Stop Patent Application, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.


37 C.F.R. SECTION 1.8(a)**37 C.F.R. SECTION 1.10***

with sufficient postage as first class mail.

as "Express Mail Post Office to Addressee"
Mailing Label No. EV420512027US

TRANSMISSION

transmitted by facsimile to the Patent and Trademark Office.



Signature

Sean Hunziker

(type or print name of person certifying)

Date: March 26, 2004

***WARNING:** Each paper or fee filed by "Express Mail" must have the number of the "Express Mail" mailing label placed thereon prior to mailing. 37 C.F.R. section 1.10(b). "Since the filing of correspondence under section 1.10 without the Express Mail mailing label thereon is an oversight that can be avoided by the exercise of reasonable care, requests for waiver of this requirement will not be granted on petition." Notice of Oct. 24, 1996, 60 Fed. Reg. 56,439, at 56,442.

Practitioner's Docket No. MPI96-031CP1DV1CPACN2M

(3) an action that otherwise closes prosecution in the application
whichever occurs first.

Accompanying this transmittal is the fee set forth in 37 C.F.R. Section 1.17(p) for submission of an information disclosure statement under Section 1.97(c). (\$180.00).

Each item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. 37 C.F.R. Section 1.97(e)(1).

No item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application and to the knowledge of the person signing the statement after making reasonable inquiry, was known to any individual designated in Section 1.56(c) more than three months prior to the filing of the information disclosure statement. 37 C.F.R. Section 1.97(e)(2).

FEE PAYMENT

2. The fee due is set forth in 37 C.F.R. Section 1.17(p) for submission of an information disclosure statement under Section 1.97(c) (\$180.00).

Applicant believes no fee is due in connection with this submission.

Fee due \$0.00

METHOD OF PAYMENT OF FEE

3. Attached is a check in the amount of \$ _____.
 Charge Account No. 501668 in the amount of \$0.00.
 A duplicate of this request is attached.

If any additional fees are due, please charge Account 501668.

March 26, 2004

MILLENNIUM PHARMACEUTICALS, INC.

By Tracy M. Sioussat
Tracy M. Sioussat
Attorney/Agent for Applicant
Reg. No. 50,609
40 Landsdowne Street
Cambridge, MA 02139
Telephone: (617) 374-7679
Facsimile - (617) 551-8820

Practitioner's Docket No. MPI96-031CP1DV1CPACN2M

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Chen, Zhijian J.
Application No.: N/A Group No.: Not Yet Assigned
Filed: March 26, 2004 Examiner: Not Yet Assigned
For: KINASE CAPABLE OF SITE-SPECIFIC PHOSPHORYLATION OF IKB-A

Mail Stop Patent Application
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

List of Sections Forming Part of This Information Disclosure Statement

The following sections are being submitted for this Information Disclosure Statement:

1. Preliminary Statements;
2. Copies of Subt. Form PTO-1449 (6 pages) cited in Serial No. 09/460,293; copies of Notice of References cited in 09/460,293 (2 pages) (parts of papers 7 and 12) and Notice of References Cited (PTO-892, part of Paper No. 11) (1 page) cited in Serial No. 08/825,559 and included in the filing of parent application Serial No. 10/052,005; copies of Substitute for Form 1449B/PTO (5 pages) cited in parent application 10/052,005; and copy of Form PTO/SB/08A (1 page) cited in parent application 10/052,005 (a total of 15 pages);

CERTIFICATION UNDER 37 C.F.R. SECTIONS 1.8(a) and 1.10*

I hereby certify that, on the date shown below, this correspondence is being:

MAILING

- deposited with the United States Postal Service in an envelope addressed to Mail Stop Patent Application, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

37 C.F.R. SECTION 1.8(a)

- with sufficient postage as first class mail.

37 C.F.R. SECTION 1.10*

- as "Express Mail Post Office to Addressee" Mailing Label No. EV420512027US

TRANSMISSION

- transmitted by facsimile to the Patent and Trademark Office.

Signature



Sean Hunziker
(type or print name of person certifying)

Date: March 26, 2004

***WARNING:** Each paper or fee filed by "Express Mail" must have the number of the "Express Mail" mailing label placed thereon prior to mailing. 37 C.F.R. section 1.10(b). "Since the filing of correspondence under section 1.10 without the Express Mail mailing label thereon is an oversight that can be avoided by the exercise of reasonable care, requests for waiver of this requirement will not be granted on petition." Notice of Oct. 24, 1996, 60 Fed. Reg. 56,439, at 56,442.

Practitioner's Docket No. MPI96-031CP1DV1CPACN2M

3. (x) Identification of Prior Application in Which Listed Information Was Already Cited and for Which No Copies Are Submitted or Need Be Submitted.

Preliminary statements

Applicants submit herewith patents, publications or other information, of which they are aware that they believe may be material to the examination of this application, and in respect of which, there may be a duty to disclose.

The filing of this information disclosure statement shall not be construed as a representation that a search has been made (37 C.F.R. section 1.97(g)), an admission that the information cited is, or is considered to be, material to patentability, or that no other material information exists.

The filing of this information disclosure statement shall not be construed as an admission against interest in any manner. Notice of January 9, 1992, 1135 O.G. 13-25, at 25.

**Identification of Prior Application in Which Listed Information Was Already Cited
and for Which No Copies Are Submitted or Need Be Submitted**

This application relies, under 35 U.S.C. section 120, on the earlier filing date of prior application Serial No. 10/052,005, filed on January 17, 2002.

The cited references were submitted to, and/or cited by, the Office in the prior application(s) and, therefore, are not required to be provided in this application. However, the undersigned will provide additional copies upon request.

March 26, 2004

MILLENNIUM PHARMACEUTICALS, INC.

By: Tracy M. Sioussat
Tracy M. Sioussat
Attorney/Agent for Applicant
Reg. No. 50, 609
40 Landsdowne Street
Cambridge, MA 02139
Telephone: (617) 374-7679
Facsimile: (617) 551-8820

COPY

Subt. For, PTO-1449

Docket Number

103576.166

Application Number

09/460,293

**INFORMATION DISCLOSURE
IN AN APPLICATION**

(Use several sheets if necessary)

Applicant
Chen, Zhijian H.

Sheet	1	OF	5	Filing Date	Group Art Unit
				September 24, 1999	- 1652

U.S. Patent Documents

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

Foreign Patent Documents

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES NO

Other Documents (Including Author, Title, Date Pertinent Pages, Etc.)

A1	Alkalay, et al., "In Vitro Stimulation of IκB Phosphorylation Is Not Sufficient to Activate NF-κB", <i>Mol. Cell. Biol.</i> , Vol. 15, No. 3, pp. 1294-1304 (1995)
A2	Alkalay, et al., "Stimulation-Dependent IκB-α Phosphorylation Marks the NF-κB Inhibitor for Degradation via the Ubiquitin-Proteasome Pathway" <i>Proc. Natl. Acad. Sci. USA</i> , Vol. 92, pp. 10599-10603 (1995)
A3	Arnason and Ellison, "Stress Resistance in <i>Saccharomyces cerevisiae</i> Is Strongly Correlated with Assembly of a Novel Type of Multiubiquitin Chain" <i>Mol. Cell. Biol.</i> , Vol. 14, No. 12, pp. 7876-7883 (1994)
A4	Auffray, et al., "IMAGE: Integrated Molecular Analysis of the Human Genome and Its Expression" <i>Sciences</i> , Vol. 318, pp. 263-272 (1995)
A5	Auphan et al., "Immunosuppression by Glucocorticoids: Inhibition of NF-κB Activity Through Induction of IκB Synthesis" <i>Science</i> , Vol. 270, pp. 286-290 (1995)
A6	Baeuerle and Henkel, "Function and Activation of NF-κB in the Immune System" <i>Annu. Rev. Immunol.</i> , Vol. 12, pp. 141-179 (1994)
A7	Baldi, et al., "Critical Role for Lysines 21 and 22 in Signal-Induced, Ubiquitin-Mediated Proteolysis of IκB-α" <i>J. Biol. Chem.</i> , Vol. 271, No. 1, pp. 376-379 (1996)
A8	Barroga et al., "Constitutive Phosphorylation of IκB-α by Casein Kinase II" <i>Proc. Natl. Acad. Sci.</i> , Vol. 92, pp. 7637-7641 (1995)
A9	Beg, et al., "Tumor Necrosis Factor and Interleukin-1 Lead to Phosphorylation and Loss of IκB-α: a Mechanism for NF-κB Activation." <i>Mol. Cell. Biol.</i> pp. 3301-3310 (1993)
A10	Belvin, et al., "Cactus Protein Degradation Mediates Drosophila Dorsal-Ventral Signaling" <i>Genes and Dev.</i> , Vol. 9, pp. 783-793 (1995)
A11	Blank, et al., "Molecular Cloning of Mitogen-activated Protein/ERK Kinase Kinases (MEKK) 2 and 3" <i>J. Biol. Chem.</i> , Vol. 271, No. 10, pp. 5361-5368 (1996)
A12	Brockman, J.A., "Coupling of a Signal Response Domain in IκB-α to Multiple Pathways for NF-κB Activation" <i>Mol. Cell. Biol.</i> , Vol. 15, No. 5 (1995)
A13	Brown, et al., "Control of IκB-α Proteolysis by Site-Specific, Signal-Induced Phosphorylation" <i>Science</i> , Vol. 267, pp. 1485-1488 (1995)
A14	Chau, "A Multiubiquitin Chain is Confined to Specific Lysine in a Targeted Short-Lived Protein" <i>Science</i> , Vol. 243, pp. 1576-1583 (1989)

EXAMINER	DATE CONSIDERED

EXAMINER: Initial if citation is considered, whether or not citation is in conformance with MPEP § 609: Draw Line through citation if not conformance and not considered. Include copy with next communication to applicant.

INFORMATION DISCLOSURE
IN AN APPLICATION

(Use several sheets if necessary)

Sheet

2

OF

5

Applicant
Chen, Zhijian H.

Filing Date

September 24, 1999

Group Art Unit

1652

B1	Chen, et al., "Multiple Ubiquitin-Conjugating Enzymes Participate in the In Vivo Degradation of the Yeast MATα2 Repressor" <i>Cell</i> , Vol. 74, pp. 357-369 (1993)
B2	Chen, et al., "Signal-Induced Site-Specific Phosphorylation Targets IκB-α to the Ubiquitin-Proteasome Pathway" <i>Genes and Dev.</i> , Vol. 9, pp. 1586-1597 (1995)
B3	Chen, et al., "Site-Specific Phosphorylation of IκB-α by a Novel Ubiquitination-Dependent Protein Kinase Activity" <i>Cell</i> , Vol. 84 (1996)
B4	Chen and Pickart, "A 25-Kilodalton Ubiquitin Carrier Protein (E2) Catalyzes Multi-ubiquitin Chain Synthesis via Lysine 48 of Ubiquitin" <i>J. Biol. Chem.</i> , Vol. 265, No. 35, pp. 21835-21842 (1990)
B5	Choi, et al., "Ste5 Tethers Multiple Protein Kinases in the MAP Kinase Cascade Required for Mating in <i>S. cerevisiae</i> " <i>Cell</i> , Vol. 78, pp. 499-512 (1994)
B6	Ciechanover, "The Ubiquitin-Proteasome Proteolytic Pathway" <i>Cell</i> , Vol. 79, pp. 13-21 (1994)
B7	Derijard, et al., "Independent Human MAP Kinase Signal Transduction Pathways Defined by MEK and MKK Isoforms" <i>Science</i> , Vol. 267, pp. 682-685 (1995)
B8	Derijard, et al., "JNK1: A Protein Kinase Stimulated by UV Light and Ha-Ras That Binds and Phosphorylates the c-Jun Activation Domain" <i>Cell</i> , Vol. 76, pp. 1025-1037 (1994)
B9	Devary, et al., "NF-κB Activation by Ultraviolet Light Not Dependent on a Nuclear Signal" <i>Science</i> , Vol. 261, pp. 1442-1445 (1993)
B10	Diaz-Meco, "ζPKC Induces Phosphorylation and Inactivation of I kappa B-alpha In Vitro" <i>EMBO J.</i> , Vol 13, No. 12, pp. 2842-2848 (1994)
B11	DiDonato, et al., "Phosphorylation of IκBa Precedes but IS Not Sufficient for Its Dissociation from NF-κB" <i>Mol. Cell. Biol.</i> , Vol. 15, No. 3, pp. 1302-1311 (1995)
B12	Dominguez, et al., "Inhibition of Protein Kinase C ζ Subspecies Blocks the Activation of an NF-κB-like activity in Xenopus Laevis Oocytes" <i>Mol. Cell. Biol.</i> , Vol. 13, No. 2, pp. 1290-1295 (1993)
B13	Finco, et al., "Inducible phosphorylation of IκBa is not sufficient for its dissociation from NF-κB and is inhibited by protease inhibitors" <i>Proc. Natl. Acad. Sci. USA</i> , Vol. 91, pp. 11884-11888 (1994)
B14	Finco and Baldwin, "κB Site-Dependent Induction of Gene Expression by Diverse Inducers of Nuclear Factor κB Requires Raf-1", <i>J. Biol. Chem.</i> , Vol. 268, No. 24, pp. 17676-17679 (1993)
B15	Finco and Baldwin, "Mechanistic Aspect of NF-κB Regulation: The Emerging Role of Phosphorylation and Proteolysis" <i>Immunity</i> , Vol. 3, pp. 263-272 (1995)
B16	Francis and Corbin, "Structure and Function of Cyclic Nucleotide-dependent Protein Kinases" <i>Annu. Rev. Physiol.</i> , Vol. 56, pp. 237-72 (1994)
B17	Ghosh and Baltimore, "Activation Invitro of NF-κB by Phosphorylation of its Inhibitor IκB" <i>Nature</i> , Vol. 344, pp. 678-682 (1990)
B18	Goldberg, Alfred L., "Functions of the Proteasome: The Lysis at the End of the Tunnel" <i>Science</i> , Vol. 268, pp. 522-523 (1995)

EXAMINER	DATE CONSIDERED
----------	-----------------

EXAMINER: Initial if citation is considered, whether or not citation is in conformance with MPEP § 609: Draw Line through citation if not conformance and not considered. Include copy with next communication to applicant.

Subt For, PTO-1449				Docket Number 103576.166	Application Number 09/460,293
INFORMATION DISCLOSURE IN AN APPLICATION <i>(Use several sheets if necessary)</i>				Applicant Chen, Zhijian H.	
Sheet	3	OF	5	Filing Date September 24, 1999	Group Art Unit 1652

c1	Gupta, et al., "Transcription Factor ATF2 Regulation by the JNK Signal Transduction Pathway" <i>Science</i> , Vol. 267, pp. 389-393 (1995)
c2	Haskill, et al., "Characterization of an Immediate-Early Gene Induced in Adherent Monocytes that Encodes IκB-like Activity" <i>Cell</i> , Vol. 65, pp. 1281-1289 (1991)
c3	Henkel, et al., "Rapid Proteolysis of IκB-α is Necessary for Activation of Transcription Factor NF-κB" <i>Nature</i> , Vol. 365, pp. 182-185 (1993)
c4	Hershko and Heller, "Occurrence of a Polyubiquitin Structure in Ubiquitin-Protein Conjugates" <i>Biochem. Biophys. Res. Commun.</i> , Vol. 128, No. 3, pp. 1079-1086 (1985)
c5	Hershko and Ciechanover, "The Ubiquitin System for Protein Degradation" <i>Annu. Rev. Biochem.</i> , Vol. 61, pp. 761-807 (1992)
c6	Hibi, et al., "Identification of an oncoprotein- and UV-responsive protein kinase that binds and potentiates the c-Jun activation domain" <i>Genes and Dev.</i> , Vol. 7, pp. 2135-2148 (1993)
c7	Higgins, et al., "Antisense inhibition of the p65 subunit of NF-κB blocks tumorigenicity and causes tumor regression" <i>Proc. Natl. Acad. Sci. USA</i> , Vol. 90, pp. 9901-9905 (1993)
c8	Hirano, et al., "MEK Kinase Is Involved in Tumor Necrosis Factor α-Induced NF-κB Activation and Degradation of IκB-α" <i>J. Biol. Chem.</i> , Vol. 271, No. 22, pp. 13234-13238 (1996)
c9	Kumar, A., et al., "Double-Stranded RNA-Dependent Protein Kinase Activates Transcription Factor NF-κB by Phosphorylating IκB" <i>Proc. Natl. Acad. Sci. USA</i> Vol. 91, pp. 6288-6292 (1994)
c10	Kuno, et al., "Identification of an IκB-α - Associated Protein Kinase in a Human Monocytic Cell Line and Determination of its Phosphorylation Sites on IκB-α" <i>Biol. Chem.</i> Vol. 270, No. 46, pp. 27914-27919 (1995)
c11	Lange-Carter, et al., "A Divergence in the MAP Kinase Regulatory Network Defined by MEK Kinase and Raf" <i>Science</i> , Vol. 260, pp. 315-319 (1993)
c12	Li and Sedivy "Raf-1 Protein Kinase Activates the NF-κB Transcription Factor By Disassociating the Cytoplasmic NF-κB-IκB complex" <i>Proc Natl Acad Sci USA</i> , Vol. 90, pp. 9247-9251 (1993)
c13	Lin, et al., "Activation of NF-κB requires proteolysis of the inhibitor IκB-α: Signal-induced phosphorylation of IκB-α alone does not release active NF-κB" <i>Proc. Natl. Acad. Sci. USA</i> , Vol. 92, pp. 552-556, (1995)
c14	Lin and Desiderio, "Regulation of V(D)J Recombination Activator Protein RAG-2 by Phosphorylation" <i>Science</i> , Vol. 260; pp. 953-959 (1993)
c15	Mellits, et al., "Proteolytic degradation of MAD3 (IκBα) and enhanced processing of the NF-κB precursor p105 are obligatory steps in the activation of NF-κB" <i>Nucl. Acid. Res.</i> , Vol. 21, No. 22, pp. 5059-5066 (1993)
c16	Miyamoto, et al., "Tumor necrosis factor α-induced phosphorylation of IκBα is a signal for its degradation but not dissociation from NF-κB" <i>Proc. Natl. Acad. Sci. USA</i> , Vol. 91, pp. 12740-12744 (1994)

EXAMINER	DATE CONSIDERED
----------	-----------------

EXAMINER: Initial if citation is considered, whether or not citation is in conformance with MPEP § 609: Draw Line through citation if not conformance and not considered. Include copy with next communication to applicant.

Subt. For, PTO-1449				Docket Number 103576.166	Application Number 09/460,293
INFORMATION DISCLOSURE IN AN APPLICATION (Use several sheets if necessary)				Applicant Chen, Zhijian H.	
Sheet	4	OF	5	Filing Date September 24, 1999	Group Art Unit 1652

D1	Nishizawa, M., et al., "Degradation of MOS by the N-terminal Proline-(Pro2)-Dependent Ubiquitin Pathway on Fertilization of Xenopus Eggs: Possible Significance of Natural Selection for Pro2 in MOS" <i>EMBO J.</i> , Vol. 12, No. 10, pp. 4021-4027 (1993)
D2	Palombella , et al., "The Ubiquitin-Proteasome Pathway is Required For Processing the NF- κ B1 Precursor Protein and the Activation of NF- κ B" <i>Cell</i> , Vol. 78, pp. 773-785 (1994)
D3	Pawlak, et al., "Characterization of a Large Population of mRNAs From Human Testis" <i>Genomics</i> , Vol. 26, pp. 151-158 (1995)
D4	Pickart and Rose, " Functional Heterogeneity of Ubiquitin Carrier Proteins" <i>J. Biol. Chem.</i> , Vol. 260, No. 3, pp. 1573-1581 (1985)
D5	Read, et al., "The Proteasome Pathway Is Required for Cytokine-Induced Endothelial-Leukocyte Adhesion Molecule Expression" <i>Immunity</i> , Vol. 2, pp. 493-506 (1995)
D6	Rodriguez, M.S., et al, "Inducible Degradation of I κ B α In Vitro and In Vivo Requires the Acidic C-Terminal Domain of the Protein" <i>Mol. Cell. Biol.</i> , Vol. 15(5), pp. 2413-2419 (1995)
D7	Scherer, et al., "Signal-Induced Degradation of I κ B- α requires site-specific Ubiquitination" <i>Natl. Acad. Sci. USA</i> , Vol. 92, pp. 11259-11263 (1995)
D8	Schreck, et al., "Reactive Oxygen Intermediates as Apparently Widely Used Messengers in the Activation of the NF- κ B Transcription Factor and HIV-1" <i>EMBO J.</i> , Vol. 10 No. 8, pp. 2247-2258 (1991)
D9	Schutze, et al., "TNF Activates NF-kappa B by Phosphatidylcholine-Specific Phospholipase C-Induced "Acidic" Sphingomyelin Breakdown" <i>Cell</i> , Vol. 71 pp.765 -777
D10	Siebenlist, et al., "Structure, Regulation and Function of NF- κ B" <i>Annu. Rev. Cell Biol.</i> , Vol. 10, pp. 405-455 (1994)
D11	Sun, et al., " NF- κ B Controls Expression of Inhibitor I κ B- α : Evidence For An Inducible Autoregulatory Pathway", <i>Science</i> , Vol. 259, pp. 1912-1915 (1993)
D12	Thanos and Maniatis, "NF- κ B: A Lesson in Family Values" <i>Cell</i> , Vol. 80, pp. 529-532 (1995)
D13	Thévenin, et al., "Induction of Nuclear Factor- κ B and the Human Immunodeficiency Virus Long Terminal Repeat by Okadaic Acid, A Specific Inhibitor of Phosphatases 1 and 2A" <i>New Biol.</i> , Vol. 2, pp. 793-800 (1990)
D14	Traenckner et al., "A Proteasome Inhibitor Prevents Activation of KF- κ B and Stabilizes a Newly Phosphorylated Form of I κ B- α That is Still Bound to NF- κ B" <i>EMBO J.</i> , Vol. 13, pp.5433-5441 (1994)
D15	Traenckner, E.B.-M.,et al, "Phosphorylation of Human I κ B- α on Serines 32 and 36 Controls I κ B- α Proteolysis and NF- κ B Activation in Response to Diverse Stimuli" " <i>EMBO J.</i> , Vol. 14, No. 12, pp. 2876-2883 (1995)
D16	Verma, et al., "Rel/NF- κ B/I κ B Family: Intimate Tales of Association and Disassociation" <i>Genes and Dev.</i> , Vol. 9 pp. 2723-2735 (1995)
D17	Wasserman, "A Conserved Signal Transduction Pathway Regulating the Activity of the Rel-Like Proteins Dorsal and NF- κ B" <i>Mol. Biol. Cell.</i> , Vol. 4, pp. 767-771 (1993)

EXAMINER	DATE CONSIDERED
----------	-----------------

EXAMINER: Initial if citation is considered, whether or not citation is in conformance with MPEP § 609: Draw Line through citation if not conformance and not considered. Include copy with next communication to applicant.

Subt. For, PTO-1449				Docket Number 103576.166	Application Number 09/460,293
INFORMATION DISCLOSURE IN AN APPLICATION (Use several sheets if necessary)				Applicant Chen, Zhijian H.	
Sheet	5	OF	5	Filing Date September 24, 1999	Group Art Unit 1652

E1	Whiteside , et al., "N- and C- Terminal Sequences Control Degradation of MAD3/IκB- α .in Response to Inducers of NF- κ B Activity" <i>Mol. Cell. Biol.</i> , Vol. 15 , No. 10, pp. 5339-5345 (1995)
E2	Yaglom, et al., " p34Cdc28-Mediated Control of Cln3 Cyclin Degradation" <i>Mol. Cell. Biol.</i> , Vol. 15, No. 2, pp. 731-741 (1995)
E3	Yang, et al., "Deficient signaling in mice devoid of double-stranded RNA-dependent Protein kinase" <i>EMBO J.</i> , Vol. 14, No. 24, pp. 6095-6106 (1995)
E4	EMBL Database entry Hs369288, Accession Number N56369, from International Search Report, International Application No. PCT/US97/04195
E5	EMBL Database entry Hs2038, Accession Number T19203, from International Search Report, International Application No. PCT/US97/04195

anthony w. sutton - z\legal\103576.166\1449.doc

EXAMINER	DATE CONSIDERED
EXAMINER: Initial if citation is considered, whether or not citation is in conformance with MPEP § 609: Draw Line through citation if not conformance and not considered. Include copy with next communication to applicant.	

COPY

Sub. Form PTO-1449 INFORMATION DISCLOSURE IN AN APPLICATION <i>(Use several sheets if necessary)</i>				Docket Number 103576.166	Application Number 09/406,293
				Applicant Chen	
Sheet	1	OF	1	Filing Date September 24, 1999	Group Art-Unit 1652

U.S. Patent Documents						
EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	5,972,674	10/26/99	Mercurio, et al.	435	194	
	6,258,579	7/10/01	Mercurio, et al.	435	194	
	6,268,194	7/31/01	Karin, et al.	435	194	
	6,242,253	6/5/01	Karin, et al.	435	325	

Foreign Patent Documents						
EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION
						YES NO
	98/08955	3/5/98	WO			
	98/37228	8/27/98	WO			

Other Documents (Including Author, Title, Date Pertinent Pages, Etc.)						
Lee et al. "Activation of the IκBα Kinase Complex by MEKK1, a Kinase of the JNK Pathway" Cell; Vol. 88; pp. 213-222 (1997)						

EXAMINER	DATE CONSIDERED
EXAMINER: Initial if citation is considered, whether or not citation is in conformance with MPEP § 609: Draw Line through citation if not conformance and not considered. Include copy with next communication to applicant.	

COPY

PTO 892 DEA/FCC 1994 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		SERIAL NUMBER 09/460,293	Art Unit 1652	Attachment to Paper Number 7
NOTICE OF REFERENCES CITED		APPLICANT(S) : Chen, et al.		

U.S. PATENT DOCUMENTS

*		DOCUMENT NUMBER	DATE	NAME(S)	CLASS	SUBCLASS	FILING DATE

FOREIGN PATENT DOCUMENTS

*		DOCUMENT NO.	DATE	COUNTRY	NAME	CLASS	SUBCLASS	PERTINENT DRW SPEC

*	OTHER REFERENCES (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)
A	Tamaoki, T, et al. (1996) Biochem. Biophys. Res. Commun. 135(2), 397-402.
B	Kase, H., et al. (1987) Biochem. Biophys. Res. Commun. 142(2), 436-440,

EXAMINER Charles L. Patterson, Jr.	DATE 2/27/01	* A COPY OF THIS REFERENCE IS NOT BEING FURNISHED WITH THIS OFFICE ACTION. (SEE MPEP SECTION 707.05(a)).
---------------------------------------	-----------------	---

COPY**Notice of References Cited**

Application/Control No.

09/406,293

Applicant(s)/Patent Under

Reexamination

CHEN, ZHIJIAN J.

Examiner

Charles L. Patterson, Jr.

Art Unit

1652

Page 1 of 1

U.S. PATENT DOCUMENTS

*	Document Number Country Code-Number-Kind Code	Date MM-YYYY	Name	Classification
A	US-	- - - - -	- - - - -	- - - - -
B	US-	- - - - -	- - - - -	- - - - -
C	US-	- - - - -	- - - - -	- - - - -
D	US-	- - - - -	- - - - -	- - - - -
E	US-	- - - - -	- - - - -	- - - - -
F	US-	- - - - -	- - - - -	- - - - -
G	US-	- - - - -	- - - - -	- - - - -
H	US-	- - - - -	- - - - -	- - - - -
I	US-	- - - - -	- - - - -	- - - - -
J	US-	- - - - -	- - - - -	- - - - -
K	US-	- - - - -	- - - - -	- - - - -
L	US-	- - - - -	- - - - -	- - - - -
M	US-	- - - - -	- - - - -	- - - - -

FOREIGN PATENT DOCUMENTS

*	Document Number Country Code-Number-Kind Code	Date MM-YYYY	Country	Name	Classification
N	- - - - -	- - - - -	- - - - -	- - - - -	- - - - -
O	- - - - -	- - - - -	- - - - -	- - - - -	- - - - -
P	- - - - -	- - - - -	- - - - -	- - - - -	- - - - -
Q	- - - - -	- - - - -	- - - - -	- - - - -	- - - - -
R	- - - - -	- - - - -	- - - - -	- - - - -	- - - - -
S	- - - - -	- - - - -	- - - - -	- - - - -	- - - - -
T	- - - - -	- - - - -	- - - - -	- - - - -	- - - - -

NON-PATENT DOCUMENTS

*	Include as applicable: Author, Title Date, Publisher, Edition or Volume, Pertinent Pages)	
U	Segel, I.H. (1975) Enzyme Kinetics, pages 89-96	
V	- - - - -	
W	- - - - -	
X	- - - - -	

A copy of this reference is not being furnished with this Office action. (See MPEP § 707.05(a).)
 Dates in MM-YYYY format are publication dates. Classifications may be US or foreign.

COPY

Notice of References Cited		Application No. 08/825,559	Applicant(s) Chen
		Examiner Nolan	Group Art Unit 1644
		Page <u>1</u> of <u>1</u>	

U.S. PATENT DOCUMENTS

*	DOCUMENT NO.	DATE	NAME	CLASS	SUBCLASS
A					
B					
C					
D					
E					
F					
G					
H					
I					
J					
K					
L					
M					

FOREIGN PATENT DOCUMENTS

*	DOCUMENT NO.	DATE	COUNTRY	NAME	CLASS	SUBCLASS
N						
O						
P						
Q						
R						
S						
T						

NON-PATENT DOCUMENTS

*	DOCUMENT (Including Author, Title, Source, and Pertinent Pages)	DATE
U	Connelly et al. Cell & Molecular Biol. Res. Vol. 41: 537-547 1975	6-95
V	Regnier et al. Cell. Vol. 90: 373-383, 1977	7-97
W		
X		

* A copy of this reference is not being furnished with this Office action.
(See Manual of Patent Examining Procedure, Section 707.05(a).)

Please type a plus sign (+) inside this box - +

PTO/SB/08B (10-96)

Approved

use through 10/31/99. OMB 0654-0031

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				Application Number	10/052,005
				Filing Date	January 17, 2002
				First Named Inventor	Chen, Zhijian J.
				Group Art Unit	1652
				Examiner Name	Patterson, Charles, L., Jr.
				Attorney Docket Number	MPI96-031CP1DV1CPACN1M
Sheet	1	of	5		

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include the name of the author (in CAPTIAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and-or country where published.	T ²
	A3	Amason, T. and Ellison, M.J., "Stress resistance in <i>Saccharomyces cerevisiae</i> is strongly correlated with assembly of a novel type of multiubiquitin chain", <i>Molecular and Cell Biology</i> , Volume 14, Number 12, pages 7876-7883 (1994)	
	A5	Auphan, N., et al., "Immunosuppression by Glucocorticoids: Inhibition of NF- κ B Activity Through Induction of I κ B Synthesis" <i>Science</i> , Volume 270, pages 286-290 (1995)	
	A6	Baeuerle, P. and Henkel, T., "Function and Activation of NF- κ B in the Immune System", <i>Annual Review of Immunology</i> , Volume 12, pages 141-179 (1994)	
	A11	Blank, J., et al., "Molecular Cloning of Mitogen-activated Protein/ERK Kinase Kinases (MEKK) 2 and 3", <i>The Journal of Biological Chemistry</i> , Volume 271, Number 10, pages 5361-5368 (1996)	
	B1	Chen, P., et al., "Multiple Ubiquitin-Conjugating Enzymes Participate in the In Vivo Degradation of the Yeast MAT α 2 Repressor", <i>Cell</i> , Volume 74, pages 357-369 (1993)	
	B4	Chen, Z., et al., "A 25-Kilodalton Ubiquitin Carrier Protein (E2) Catalyzes Multiubiquitin Chain Synthesis via Lysine 48 of Ubiquitin", <i>The Journal of Biological Chemistry</i> , Volume 265, Number 35, pages 21835-21842 (1990)	
	B5	Choi, K., et al., "Ste5 Tethers Multiple Protein Kinases in the MAP Kinase Cascade Required for Mating in <i>S. cerevisiae</i> ", <i>Cell</i> , Volume 78, pages 499-512 (1994)	
	B7	Derjard, B., et al., "Independent Human MAP Kinase Signal Transduction Pathways Defined by MEK and MKK Isoforms" <i>Science</i> , Volume 267, pages 682-685 (1995)	
	B8	Derjard, B., et al., "JNK1: A Protein Kinase Stimulated by UV Light and Ha-RAS That Binds and Phosphorylates the c-Jun Activation Domain", <i>Cell</i> , Volume 76, pages 1025-1037 (1994)	
	B11	DiDonato, J., et al., "Phosphorylation of I κ B α Precedes but Is Not Sufficient for Its Dissociation from NF- κ B", <i>Molecular and Cellular Biology</i> , Volume 15, Number 3, pages 1302-1311 (1995)	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation design number. ²Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, D.C. 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

Please type a plus sign (+) inside this box -

+

PTO/SB/08B (10-96)

Approved for use through 10/31/99. OMB 0654-0031

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>					
Sheet	2	of	5	Application Number	10/052005
				Filing Date	January 17, 2002
				First Named Inventor	Chen, Zhijian J.
				Group Art Unit	1652
				Examiner Name	Patterson, Charles L., Jr.
				Attorney Docket Number	MPI96-031CP1DV1CPACN1M

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. ¹	Include the name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		T ²
	B13	Finco, T., et al., "Inducible phosphorylation of IκBα is not sufficient for its dissociation from NF-κB and is inhibited by protease inhibitors", Proceedings of the National Academy of Sciences USA, Volume 91, pages 11884-11888 (1994)		
	B15	Finco, T., et al., "Mechanistic Aspects of NF-κB Regulation: The Emerging Role of Phosphorylation and Proteolysis", Immunity, Volume 3, pages 263-272 (1995)		
	B16	Francis, S. and Corbin, D., "Structure and Function of Cyclic Nucleotide-Dependent Protein Kinases" Annual Review of Physiology, Volume 56, pages 237-272 (1994)		
	B18	Goldberg, A., "Functions of the Proteasome: The Lysis at the End of the Tunnel", Science, Volume 268, pages 522-523 (1995)		
	C1	Gupta, S., et al., "Transcription Factor ATF2 Regulation by the JNK Signal Transduction Pathway", Science, Volume 267, pages 389-393 (1995)		
	C2	Haskill, S., et al., "Characterization of an Immediate-Early Gene Induced in Adherent Monocytes That Encodes IκB-like Activity", Cell, Volume 65, pages 1281-1289 (1991)		
	C4	Hershko, A. and Heller, H., "Occurrence of a Polyubiquitin Structure in Ubiquitin-Protein Conjugates", Biochemical and Biophysical Research Communications, Volume 128, Number 3, pages 1079-1086 (1985)		
	C6	Hibi, M., et al., "Identification of an oncoprotein- and UV-responsive protein kinase that binds and potentiates the c-Jun activation domain" Genes and Development, Volume 7, pages 2135-2148 (1993)		
	C7	Higgins, K., et al., "Antisense inhibition of the p65 subunit of NF-κB blocks tumorigenicity and causes tumor regression", Proceedings of the National Academy of Sciences USA, Volume 90, pages 9901-9905 (1993)		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation design number. ²Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, D.C. 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

Please type a plus sign (+) inside this box -



PTO/SB/08B (10-96)

Approved for use through 10/31/99. OMB 0654-0031

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>					
Sheet	3	of	5	Application Number	10/052005
				Filing Date	January 17, 2002
				First Named Inventor	Chen, Zhijian J.
				Group Art Unit	1652
				Examiner Name	Patterson, Charles L., Jr.
				Attorney Docket Number	MPI96-031CP1DV1CPACN1M

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. ¹	Include the name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and-or country where published.		T ²
	C6	Hirano, M., et al., "MEK-Kinase Is Involved in Tumor Necrosis Factor α -Induced NF- κ B Activation and Degradation of I κ B- α ", The Journal of Biological Chemistry, Volume 217, Number 22, pages 13234-13238 (1996)		
	C11	Lange-Carter, C.A., et al., "A Divergence in the MAP Kinase Regulatory Network Defined by MEK Kinase and Raf", Science, Volume 260, pages 315-319 (1993)		
	C13	Lin, Y.-C., et al., "Activation of NF- κ B requires proteolysis of the inhibitor I κ B- α : Signal-induced phosphorylation of I κ B- α alone does not release active NF- κ B", Proceedings of the National Academy of Sciences USA, Volume 92, pages 552-556 (1995)		
	C15	Mellits, K-H., et al., "Proteolytic degradation of MAD3 (I κ B α) and enhanced processing of the NF- κ B precursor p105 are obligatory steps in the activation of NF- κ B", Nucleic Acids Research, Volume 21, Number 22, pages 5059-5066 (1993)		
	C16	Miyamoto, S., et al., "Tumor necrosis factor α -induced phosphorylation of I κ B α is a signal for its degradation but not dissociation from NF- κ B", Proceedings of the National Academy of Sciences USA, Volume 91, pages 12740-12744 (1994)		
	D5	Read, M.A., et al., "The Proteasome Pathway is Required for Cytokine-Induced Endothelial-Leukocyte Adhesion Molecule Expression", Immunity, Volume 2, pages 493-506 (1995)		
	D10	Siebenlist, U., et al., "Structure, Regulation and Function of NF- κ B", Annual Review of Cell Biology, Volume 10, pages 405-455 (1994)		
	D12	Thanos, D. and Maniatis, T., "NF- κ B: A Lesson in Family Values", Cell, Volume 80, pages 529-532 (1995)		
	D13	Thevenin, C., et al., "Induction of Nuclear Factor- κ B and the Human Immunodeficiency Virus Long Terminal Repeat by Okadaic Acid, a Specific Inhibitor of Phosphatases 1 and 2A", New Biologist, Volume 2, Number 9, pages 793-800 (1990)		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation design number. ²Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, D.C. 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

Please type a plus sign (+) inside this box



PTO/SB/08B (10-96)

Approved for use through 10/31/99. OMB 0654-0031

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>		Application Number	10/052005
		Filing Date	January 17, 2002
		First Named Inventor	Chen, Zhijian J.
		Group Art Unit	1652
		Examiner Name	Patterson, Charles L., Jr.
Sheet	4	of	5
		Attorney Docket Number	MPI96-031CP1DV1CPACN1M

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. ¹	Include the name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and-or country where published.		T ²
	D15	Traenckner, E.B., et al., "Phosphorylation of Human IκB-α on Serines 32 and 36 Controls IκB-α Proteolysis and NF-κB Activation in Response to Diverse Stimuli", The EMBO Journal, Volume 14, Number 12, pages 2876-2883 (1995)		
	E3	Yang, Y.-L., et al., "Deficient signaling in mice devoid of double-stranded RNA-dependent protein kinase", The EMBO Journal, Volume 14, Number 24, pages 6095-6106 (1995)		
	F1	Xu, S., et al., "Cloning of rat MEK kinase 1 cDNA reveals an endogenous membrane-associated 195-kDa protein with a large regulatory domain", Proceedings of the National Academy of Sciences USA, Volume 93, pages 5291-5295 (1996)		
	F2	Khoshnan, A., et al., "The Physical Association of Protein Kinase Cθ with a Lipid Raft-Associated Inhibitor of κB Factor Kinase (IKK) Complex Plays a Role in the Activation of the NF-κB Cascade by TCR and CD28 ^{1*} ", The Journal of Immunology, Volume 165, pages 6933-6940 (2000)		
	F3	DiDonato, J.A., et al., "A Cytokine-responsive IκB kinase that Activates the Transcription Factor NF-κB", Nature, Volume 388, pages 548-554 (August 1997)		
	F4	Miller, B.S. and Zandi, E., "Complete Reconstitution of Human IκB Kinase (IKK) Complex in Yeast", The Journal of Biological Chemistry, Volume 276, Number 39, pages 36320-36326 (September 28, 2001)		
	F5	Fu, D.-X., et al., "Human T-lymphotropic Virus Type I Tax Activates I-κB Kinase by Inhibiting I-κB Kinase-associated Serine/Threonine Protein Phosphatase 2A", The Journal of Biological Chemistry, Volume 278, Number 3, pages 1487-1493 (January 17, 2003)		
	F6	Storz, P. and Toker, A., "Protein kinase D mediates a stress-induced NF-κB Activation and Survival Pathway", The EMBO Journal, Volume 22, Number 1, pages 109-120 (2003)		
	F7	Yang, J., et al., "The Essential Role of MEKK3 in TNF-induced NF-κB Activation", Nature Immunology, Volume 2, Number 7, pages 620-624 (July 2000)		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation design number. ²Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, D.C. 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO				Complete If Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				Application Number	10/052005
				Filing Date	January 17, 2002
				First Named Inventor	Chen, Zhijian J.
				Group Art Unit	1652
				Examiner Name	Patterson, Charles L., Jr.
Sheet	5	of	5	Attorney Docket Number	MPI96-031CP1DV1CPACN1M

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. ¹	Include the name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		T ²
	F8	Zhao, Q. and Lee, F.S., "Mitogen-activated Protein Kinase/ERK Kinase Kinases 2 and 3 Activate Nuclear Factor- κ B through I κ B Kinase- α and I κ B Kinase- β ", The Journal of Biological Chemistry, Volume 274, Number 13, pages 8355-8358 (March 26, 1999)		
	F9	Tojima, Y., et al., "NAK is an I κ B kinase-activating kinase", Nature, Volume 404, pages 778-782 (April 13, 2000)		
	F10	Wang, C., et al., "TAK1 is a Ubiquitin-dependent kinase of MKK and IKK", Nature, Volume 412, pages 346-351 (July 19, 2001)		
	F11	Regnier, C.H., et al., "Identification and Characterization of an I κ B Kinase", Cell, Volume 90, pages 373-383 (July 25, 1997)		
	F12	Connelly, M.A. and Marcu, K.B., "CHUK, A New Member of the Helix-loop-helix and Leucine Zipper Families of Interacting Proteins, Contains a Serine-Threonine Kinase Catalytic Domain", Cellular and Molecular Biology Research, Volume 41, Number 6, pages 537-549 (1995)		

Examiner Signature		Date Considered
--------------------	--	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation design number. ²Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, D.C. 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

Please type a plus sign (+) inside this box

+

FTC/SB/06A (10-96)

Approved for use through 10/31/99. OMB 0654-0031

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO				<i>Complete if Known</i>	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number	10/052,005
				Filing Date	January 17, 2002
				First Named Inventor	Chen, Zhijian J.
				Group Art Unit	1652
				Examiner Name	Patterson, Charles L., Jr.
				Attorney Docket Number	MPI96-031CP1DV1CPACN1M
(use as many sheets as necessary)					
Sheet	1	of	1		

U.S. PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS

Examiner Signature		Date Considered	
-------------------------------	--	----------------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation design number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁸Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, D.C. 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.